Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence

Expert Opinion on Pharmacotherapy
Lingaku LeeRobert T Jensen

Abstract

Since the initial approval of everolimus in 2011, there have been a number of important changes in therapeutic/diagnostic modalities as well as classification/staging systems of neuroendocrine tumors (NETs), which can significantly impact the use of everolimus in patients with advanced NETs. Areas covered: The efficacy of everolimus monotherapy and combination therapy demonstrated in clinical studies involving patients with advanced NETs are reviewed. Several factors affecting everolimus use are described including: the development and routine use of NET classification/staging systems; widespread use of molecular imaging modalities; side effects; drug resistance; and the availability of other treatment options. Furthermore, the current position of everolimus in the treatment approach is discussed, taking into account the recommendations from the recent guidelines. Expert opinion: Although everolimus demonstrated its high efficacy and tolerability in the RADIANT trials and other clinical studies, there still remain a number of controversies related to everolimus treatment in the management of NETs. The synergistic anti-growth effect of other agents in combination with everolimus or its effect on overall survival have not been es...Continue Reading

References

Jun 1, 1988·Gastroenterology·T von SchrenckJ D Gardner
Jan 1, 1984·Annals of Internal Medicine·M J CollenR T Jensen
Feb 6, 2003·Cancer·Irvin M ModlinMark Kidd
Jan 30, 2004·Clinical Pharmacokinetics·Gabriele I KirchnerMichael P Manns
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Feb 14, 2006·Cell·Stephan WullschlegerMichael N Hall
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chiaki TanakaHeidi A Lane
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne O'DonnellIan Judson
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dik J KwekkeboomEric P Krenning
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Aug 16, 2008·Gastroenterology·David C Metz, Robert T Jensen
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoFunda Meric-Bernstam
Oct 29, 2008·Proceedings of the National Academy of Sciences of the United States of America·Andrew Y ChooJohn Blenis
Jan 9, 2009·The New England Journal of Medicine·Matthew H KulkeJames C Yao
Apr 3, 2009·Nature Reviews. Molecular Cell Biology·Xiaoju Max Ma, John Blenis
Aug 7, 2009·Cancer Chemotherapy and Pharmacology·Takashi ShidaMasaru Miyazaki
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edoardo MissiagliaAldo Scarpa
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoBertram Wiedenmann
Feb 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter J Houghton
Jul 29, 2010·The Journal of Clinical Investigation·Federica Di NicolantonioAlberto Bardelli
Jul 29, 2010·Pancreas·Matthew H KulkeUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Jul 29, 2010·Pancreas·Jonathan R StrosbergUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Sep 8, 2010·Endocrine-related Cancer·Luisella RighiMauro Papotti
Nov 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ahmad TarhiniAthanassios Argiris
Nov 5, 2010·The New England Journal of Medicine·Darcy A KruegerDavid Neal Franz
Dec 17, 2010·Endocrine-related Cancer·Atsuko KasajimaWilko Weichert
Dec 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CapdevilaJ Tabernero
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Feb 22, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sung-Hsin KuoAnn-Lii Cheng

❮ Previous
Next ❯

Citations

Apr 30, 2019·Endocrine Connections·Giulia BrescianiTeresa Gagliano
Sep 25, 2019·Cancers·Periklis KatopodisEmmanouil Karteris
Jan 16, 2020·International Journal of Molecular Sciences·Anubhab MukherjeeSudip Mukherjee
Aug 30, 2020·World Journal of Surgery·Jonathan Koea, UNKNOWN Commonwealth Neuroendocrine Tumour Research Collaborative (CommNETs) Surgical Section
Dec 12, 2020·Frontiers in Endocrinology·Sara ZaniniGiovanna Bermano
Mar 26, 2021·Advanced Healthcare Materials·Özlem ŞenGianni Ciofani
Apr 4, 2021·Cancers·Sarah Christine Elisabeth WrightPieter Johan Adam Eichhorn
May 6, 2019·Annales d'endocrinologie·David Romano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.